EPIGENETIC REGULATION OF GENE EXPRESSION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: THERAPEUTIC PERSPECTIVES

Head and neck tumors (HNT)  include cancers of nasal cavity, oral cavity, larynx, pharynx, cervical esophagus, paranasal sinuses, and salivary glands; in most of the cases HNT are presented by squamous cell carcinoma. Despite the fact that tumors of head and neck are generally available for visual inspection, about 60–70 % of the patients are diagnosed with it at advanced (III or IV) stages of the disease. Unfortunately, optimization of diagnostic algorithms and wide implementation of instrumental diagnostics (ultrasound examination, computed tomography, fiber endoscopy) do not improve the situation. Current trends in HNT  incidence and mortality in Russia (increasing of both absolute and relative figures of incidence and mortality over the last 10–12 years) clearly demonstrate its social importance. Available epidemiological data suggests the obvious need for fundamental studies devoted to HNT pathogenesis as well as for development of novel meth ods of pathogenetic therapy. Along with the importance of investigation of typical for HNT genetic abnormalities, we should also stress studying of epigenetic regulation disorders in tumor cells because of its particular practical value.

This review is aimed to analyze the relationship between different mechanisms of epigenetic regulation of gene expression, and to evaluate this relationship in squamous cell HNT.  In terms of new therapy methods development it is important to understand the complex nature of epigenetic control of gene expression as soon as it allows to create and implement optimal methods of chemotherapy. For instance, the antitumor effect of butyric acid could be theoretically modified or enhanced by the inhibitors of miR-17-92a or miR-31 mimics. In this case one of the drugs can be administrated locally, and the other one – systemically, this possibility can help to reach maximum therapeutic effect in the tumor tissue. The main aim of this review was to present mechanisms, development prospects and application possibilities of HNT epigenetic therapy, which can be soon offered to clinicians.

1. Суконко О.Г., Красный С.А. Алгоритмы диагностики и лечения злокачественных новообразований. Под ред. О.Г. Суконко, С.А. Красного. Минск, 2012. С. 13–30. [Sukonko O.G., Krasnyy S.A. Algorithms of diagnostics and treatment of malignant neoplasms. Eds. by O.G. Sukonko, S.A. Krasnyy. Minsk, 2012. Pp. 13–30. (In Russ.)].

2. Вельшер Л.З., Матякин Е.Г., Дудицкая Т.К., Поляков Б.И. Онкология. М.: ГЭОТАР-Медиа, 2009. 512 с. [Vel’sher L.Z., Matyakin E.G., Duditskaya T.K., Polyakov B.I. Oncology. Moscow: GEOTAR-Media, 2009. 512 p. (In Russ.)].

3. Bychkov V.A., Nikitina E.G., Ibragimova M.K. et al. Comprehensive meta-analytical summary on human papillomavirus association with head and neck cancer. Exp Oncol 2016;38(2):68–72.

4. Jalouli J., Jalouli M.M., Sapkota D. et al. Human papilloma virus, herpes simplex virus and epstein barr virus in oral squamous cell carcinoma from eight different countries. Anticancer Res 2012:32(2):571–80.

5. Кропотов М.А. Общие принципы лечения больных первичным раком головы и шеи. Практическая онкология 2003;4(1):1–8. [Kropotov M.A. General principles of treatment of patients with primary cancer of the head and neck. Prakticheskaya onkologiya = Practical Oncology 2003;4(1): 1–8. (In Russ.)].

6. Алферов В.С. Органосохраняющие методы лечения рака гортани. М., 1993. 350 c. [Alferov V.S. Organ-preserving methods of treatment of cancer of the larynx. Moscow, 1993. 350 p. (In Russ.)].

7. Mудунов А.М. Сравнительная оценка эффективности неоадъювантной химиотерапии в комплексном и комбинированном лечении плоскоклеточного рака слизистой оболочки полости рта и ротоглотки. Дис. … канд. мед. наук. М., 2002. 25 с. [Mudunov A.M. Comparative evaluation of neoadjuvant chemotherapy in the complex and combined treatment of squamous cell carcinoma of the mucosa of the oral cavity and oropharynx. Thesis … of candidate of medicine. Moscow, 2002. 25 p. (In Russ.)].

8. Практические рекомендации по лекарственному лечению опухолей головы и шеи. Злокачественные опухоли 2015;(4s):47–54. [Practical recommendations for drug treatment of tumors of the head and neck. Zlokachestvennye opukholi = Malignant Tumors 2015;(4s):47–54. (In Russ.)].

9. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2016. [Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2014 (morbidity and mortality). Eds. by: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow, 2016. (In Russ.)].

10. Ванюшин Б.Ф. Эпигенетика сегодня и завтра. Вавиловский журнал генетики и селекции 2013;17(4/2):805–32. [Vanyushin B.F. Epigenetics today and tomorrow. Vavilovskiy zhurnal genetiki i selektsii = Vavilov Journal of Genetics and Plant Breeding 2013;17(4/2):805–32. (In Russ.)].

11. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148–59. DOI: 10.1056/NEJMra072067.

12. Fan C.Y. Epigenetic alterations in head and neck cancer: prevalence, clinical significance, and implications. Curr Oncol Rep 2004;6(2):152–61.

13. Bakhtiar S.M., Ali A., Barh D. Epigenetics in head and neck cancer. Methods Mol Biol 2015;1238:751–69. DOI: 10.1007/978-1-4939-1804-1_39.

14. Demokan S., Dalay N. Role of DNA methylation in head and neck cancer. Clin Epigenetics 2011;2(2):123–50. DOI: 10.1007/s13148-011-0045-3.

15. Shridhar K., Walia G.K., Aggarwal A. et al. DNA methylation markers for oral pre-cancer progression: A critical review. Oral Oncol 2016;53:1–9. DOI: 10.1016/j.oraloncology.2015.11.012.

16. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007;26(37):5420–32.

17. Chen Y.W., Kao S.Y., Wang H.J., Yang M.H. Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma. Cancer 2013;119(24):4259-67. DOI: 10.1002/cncr.28356.

18. URL: http://www.mirbase.org/.

19. Gunaratne P.H., Creighton C.J., Watson M., Tennakoon J.B. Large-scale integration of microRNA and gene expression data for identification of enriched microRNA-mRNA associations in biological systems. Methods Mol Biol 2010;667:297–315. DOI: 10.1007/978-1-60761-811-9_20.

20. Gulyaeva L.F., Kushlinskiy N.E. Regulatory mechanisms of microRNA expression. J Transl Med 2016;14(1):143. DOI: 10.1186/s12967-016-0893-x.

21. Di Leva G., Garofalo M., Croce C.M. MicroRNAs in cancer. Annu Rev Pathol 2014;9:287–314. DOI: 10.1146/annurev-pathol-012513-104715.

22. Courthod G., Franco P., Palermo L. et al. The role of microRNA in head and neck cancer: current knowledge and perspectives. Molecules 2014;19(5):5704–16. DOI: 10.3390/molecules19055704.

23. John K., Wu J., Lee B.W., Farah C.S. MicroRNAs in Head and Neck Cancer. Int J Dent 2013;2013:650218. DOI: 10.1155/2013/650218.

24. Choi J.D., Lee J.S. Interplay between Epigenetics and Genetics in Cancer. Genomics Inform 2013;11(4):164–73. DOI: 10.5808/GI.2013.11.4.164.

25. Shen H., Laird P.W. Interplay between the cancer genome and epigenome. Cell 2013;153(1):38–55.

26. Chuang J.C., Jones P.A. Epigenetics and microRNAs. Pediatr Res 2007;61(5 Pt 2):24R–29R.

27. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010;31(1):27–36.

28. Baylin S.B., Jones P.A. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 2016;8(9):a019505. DOI: 10.1101/cshperspect.a019505.

29. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5(1):37–50.

30. Cedar H., Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009;10(5):295–304. DOI: 10.1038/nrg2540.

31. Nan X., Ng H.H., Johnson C.A. et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393(6683):386–9.

32. Fuks F., Hurd P.J., Wolf D. et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003;278(6):4035–40.

33. Fuks F., Burgers W.A., Brehm A. et al. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000;24(1):88–91.

34. Sato F., Tsuchiya S. Meltzer S.J., Shimizu K. MicroRNAs and epigenetics. FEBS J 2011;278(10):1598–609. DOI: 10.1111/j.1742-4658.2011.08089.x.

35. Wu L., Mao L., Qi Y. Roles of dicer-like and argonaute proteins in TAS-derived small interfering RNA-triggered DNA methylation. Plant Physiol 2012;160(2):990–9. DOI: 10.1104/pp.112.200279.

36. Wu L., Zhou H., Zhang Q. et al. DNA methylation mediated by a microRNA pathway. Mol Cell 2010;38(3):465–75. DOI: 10.1016/j.molcel.2010.03.008.

37. Wong T.S., Gao W., Chan J.Y. Interactions between E-cadherin and microRNA deregulation in head and neck cancers: the potential interplay. Biomed Res Int 2014;2014:126038. DOI: 10.1155/2014/126038.

38. Entrevan M., Schuettengruber B., Cavalli G. Regulation of Genome Architecture and Function by Polycomb Proteins. Trends Cell Biol 2016;26(7):511–25. DOI: 10.1016/j.tcb.2016.04.009.

39. Simon J.A., Kingston R.E. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009;10(10):697–708. DOI: 10.1038/nrm2763.

40. Li X., Lin Y., Yang X. et al. Long noncoding RNA H19 regulates EZH2 expression by interacting with miR-630 and promotes cell invasion in nasopharyngeal carcinoma. Biochem Biophys Res Commun 2016;473(4):913–9. DOI: 10.1016/j.bbrc.2016.03.150.

41. Sander S., Bullinger L., Klapproth K. et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008;112(10):4202–12. DOI: 10.1182/blood-2008-03-147645.

42. Varambally S., Cao Q., Mani R.S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322(5908):1695–9. DOI: 10.1126/science.1165395.

43. Siddique H.R., Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 2012;30(3):372–8. DOI: 10.1002/stem.1035.

44. Lundberg M., Renkonen S., Haglund C. et al. Association of BMI-1 and p16 as prognostic factors for head and neck carcinomas. Acta Otolaryngol 2016;136(5):501–5. DOI: 10.3109/00016489.2015.1122227.

45. Hauser B., Zhao Y., Pang X. et al. Functions of MiRNA-128 on the regulation of head and neck squamous cell carcinoma growth and apoptosis. PLoS One 2015;10(3):e0116321. DOI: 10.1371/journal.pone.0116321.

46. Yu X., Jiang X., Li H. et al. miR-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like cells by suppressing stem renewal factor Bmi-1. Stem Cells Dev 2014;23(6):576–85. DOI: 10.1089/scd.2013.0308.

47. Swierczynski S., Klieser E., Illig R. et al. Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases. Expert Opin Biol Ther 2015;15(5):651–64. DOI: 10.1517/14712598.2015.1025047.

48. Le J.M., Squarize C.H., Castilho R.M. Histone modifications: Targeting head and neck cancer stem cells. World J Stem Cells 2014;6(5):511–25. DOI: 10.4252/wjsc.v6.i5.511.

49. Cho J.H., Dimri M., Dimri G.P. MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence. J Biol Chem 2015;290(16):10555–67. DOI: 10.1074/jbc.M114.624361.

50. Koumangoye R.B., Andl T., Taubenslag K.J. et al. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. Mol Cancer 2015;14:24. DOI: 10.1186/s12943-014-0284-y.

51. Taby R., Issa J.P. Cancer epigenetics. CA Cancer J Clin 2010;60(6):376–92. DOI: 10.3322/caac.20085.

52. Berdasco M., Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 2010;19(5):698–711. DOI: 10.1016/j.devcel.2010.10.005.

53. Guil S., Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 2009;41(1):87–95. DOI: 10.1016/j.biocel.2008.09.005.

54. Roman-Gomez J., Agirre X., Jiménez-Velasco A. et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol 2009;27(8):1316–22. DOI: 10.1200/JCO.2008.19.3441.

55. Bandres E., Agirre X., Bitarte N. et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009;125(11):2737–43. DOI: 10.1002/ijc.24638.

56. Lujambio A., Calin G.A., Villanueva A. et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008;105(36):13556–61. DOI: 10.1073/pnas.0803055105.

57. Lehmann U., Hasemeier B., Christgen M. et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 2008;214(1):17–24.

58. Zhu D.D., Zhang J., Deng W. et al. Significance of NF-kappaB activation in immortal-ization of nasopharyngeal epithelial cells. Int J Cancer 2016;138(5):1175–85. DOI: 10.1002/ijc.29850.

59. He L., He X., Lim L.P. et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447(7148):1130–4.

60. Chang T.C., Wentzel E.A., Kent O.A. et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26(5):745–52.

61. Lodygin D., Tarasov V., Epanchintsev A. et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008;7(16):2591–600.

62. Saito Y., Liang G., Egger G. et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006;9(6):435–43.

63. Toyota M., Suzuki H., Sasaki Y. et al. Epigenetic silencing of microRNA-34b/c and Bcell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008;68(11):4123–32. DOI: 10.1158/0008-5472.CAN-08-0325.

64. Jia L.F., Wei S.B., Mitchelson K. et al. miR-34a inhibits migration and invasion of tongue squamous cell carcinoma via targeting MMP9 and MMP14. PLoS One 2014;9(9):e108435. DOI: 10.1371/journal.pone.0108435.

65. Cao X., Pfaff S.L., Gage F.H. A functional study of miR-124 in the developing neural tube. Genes Dev 2007;21(5):531–6.

66. Cheng Y., Li Y., Nian Y. et al. STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells. BMC Cancer 2015;15:306. DOI: 10.1186/s12885-015-1303-0.

67. Peng X.H., Huang H.R., Lu J. et al. MiR-124 suppresses tumor growth and metastasis by targeting Foxq1 in nasopharyngeal carcinoma. Mol Cancer 2014;13:186. DOI: 10.1186/1476-4598-13-186.

68. Shin K.H., Pucar A., Kim R.H. et al. Identification of senescence-inducing microRNAs in normal human keratinocytes. Int J Oncol 2011;39(5):1205–11. DOI: 10.3892/ijo.2011.1111.

69. Ando T., Yoshida T., Enomoto S. et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer DOI: 10.1002/ijc.24219.

70. Dang J., Bian Y.Q., Sun J.Y. et al. Micro RNA-137 promoter methylation in oral lichen planus and oral squamous cell carcinoma. J Oral Pathol Med 2013;42(4):315–21. DOI: 10.1111/jop.12012.

71. Kozaki K., Imoto I., Mogi S. et al. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008;68(7):2094-105. DOI: 10.1158/0008-5472.CAN-07-5194.

72. Hezova R., Kovarikova A., Srovnal J. et al. Diagnostic and prognostic potential of miR- 21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagus. Diagn Pathol 2015;10:42.

73. Wellner U., Schubert J., Burk U.C. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009;11(12):1487–95.

74. Wiklund E.D., Bramsen J.B., Hulf T. et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011;128(6):1327–34. DOI: 10.1002/ijc.25461.

75. Tamagawa S., Beder L.B., Hotomi M. et al. Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma. Int J Mol Med 2014;33(4):879–86. DOI: 10.3892/ijmm.2014.1625.

76. Bueno M.J.1, Pérez de Castro I., Gómez de Cedrón M. et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL oncogene expression. Cancer Cell 2008;13(6):496–506. DOI: 10.1016/j.ccr.2008.04.018.

77. Furuta M., Kozaki K.I., Tanaka S. et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010;31(5):766–76. DOI: 10.1093/carcin/bgp250.

78. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008;269(1):7–17.

79. Erlich R.B., Rickwood D., Coman W.B. et al. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemother Pharmacol 2009;63(3):381–9. DOI: 10.1007/s00280-008-0747-1.

80. Starkova J., Madzo J., Cario G. et al. The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells. Clin Cancer Res 2007;13(6):1726–35.

81. Cinatl J. Jr, Cinatl J., Driever P.H. et al. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 1997;8(10):958–63.

82. Blaheta R.A., Michaelis M., Driever P.H., Cinatl J. Jr. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005;25(4):383–97.

83. Hrebackova J., Hrabeta J., Eckschlager T. Valproic acid in the complex therapy of malig nant tumors. Curr Drug Targets 2010;11(3):361–79.

84. Witt D., Burfeind P., von Hardenberg S. et al. Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. Carcinogenesis 2013;34(5):1115–24. DOI: 10.1093/carcin/bgt019.

85. Gan C.P., Hamid S., Hor S.Y. et al. Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head Neck 2012;34(3):344–53. DOI: 10.1002/hed.21734.

86. Lee S.H., Nam H.J., Kang H.J. et al. Valproic acid suppresses the self-renewal and proliferation of head and neck cancer stem cells. Oncol Rep 2015;34(4):2065–71. DOI: 10.3892/or.2015.4145.

87. Oikawa H., Goh W.W., Lim V.K. et al. Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1. Neurochem Int 2015;91:62–71. DOI: 10.1016/j.neuint.2015.10.010.

88. Trécul A., Morceau F., Gaigneaux A. et al. Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networks. Biochem Pharmacol 2014;92(2):299–311. DOI: 10.1016/j.bcp.2014.07.035.

89. Datta J., Islam M., Dutta S. et al. Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs. Oral Oncol 2016;56:32–9. DOI: 10.1016/j.oraloncology.2016.02.015.

90. Datta J., Smith A., Lang J.C. et al. microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase Cɛ. Oncogene 2012;31(36):4045–53. DOI: 10.1038/onc.2011.565.

91. Piao L., Zhang M., Datta J. et al. Lipidbased nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol Ther 2012;20(6):1261–9. DOI: 10.1038/mt.2012.67.

92. Jiang L., Liu X., Kolokythas A. et al. Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer 2010;127(3):505–12. DOI: 10.1002/ijc.25320.

93. Song T., Zhang X., Wang C. et al. MiR-138 suppresses expression of hypoxia-inducible factor 1alpha (HIF-1alpha) in clear cell renal cell carcinoma 786-O cells. Asian Pac J Cancer Prev 2011;12(5):1307–11.

94. Liu X., Wang C., Chen Z. et al. Micro RNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J 2011;440(1):23–31. DOI: 10.1042/BJ20111006.

95. Alhazzazi T.Y., Kamarajan P., Joo N. et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011;117(8):1670–8. DOI: 10.1002/cncr.25676.

96. Cheng Y., Mai J., Hou T., Ping J. Micro RNA-421 induces hepatic mitochondrial dysfunction in non-alcoholic fatty liver disease mice by inhibiting sirtuin 3. Biochem Biophys Res Commun 2016;474(1):57–63. DOI: 10.1016/j.bbrc.2016.04.065.

97. Sengupta S., Muir J.G., Gibson P.R. Does butyrate protect from colorectal cancer? J Gastroenterol Hepatol 2006;21(1 Pt 2): 209–18.

98. Humphreys K.J., Cobiac L., Le Leu R.K. et al. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog 2013;52(6):459–74. DOI: 10.1002/mc.21879.

99. Hu S., Liu L., Chang E.B. et al. Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells. Mol Cancer 2015;14:180. DOI: 10.1186/s12943-015-0450-x.

100. Chen H.C., Chen G.H., Chen Y.H. et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer 2009;100(6):1002–11. DOI: 10.1038/sj.bjc.6604948.